Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Asthma Biomarker Study

Completed

Conditions: Asthma

Interventions: Procedure: Biofluid sampling

First Posted Date: 2015-03-19

Last Posted Date: 2018-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 69

Registration Number: NCT02392481

Locations: 🇬🇧
352.2087.44001 Boehringer Ingelheim Investigational Site, Leicester, United Kingdom
🇬🇧
352.2087.44004 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧
352.2087.44002 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom

and more 1 locations

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 425809

First Posted Date: 2015-03-10

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02383888

Locations: 🇰🇷
1346.4.82001 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Trial of Afatinib in Pediatric Tumours

Phase 1

Completed

Conditions: Neuroectodermal Tumors
Rhabdomyosarcoma

Interventions: Drug: afatinib

First Posted Date: 2015-02-26

Last Posted Date: 2021-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02372006

Locations: 🇫🇷
INS Curie, Paris, France
🇦🇺
Sydney Childrens Hospital, Randwick, New South Wales, Australia
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 25 locations

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: JARDIANCE®

First Posted Date: 2015-02-20

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 419

Registration Number: NCT02367131

Locations: 🇯🇵
NISND Center, Multiple Locations, Japan

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809

First Posted Date: 2015-02-13

Last Posted Date: 2015-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02362516

Locations: 🇧🇪
1346.3.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran Etexilate 150mg
Drug: Warfarin

First Posted Date: 2015-01-28

Last Posted Date: 2018-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 678

Registration Number: NCT02348723

Locations: 🇺🇸
Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States
🇺🇸
Southwest Florida Research, LLC, Naples, Florida, United States
🇺🇸
University of California, San Francisco, California, United States

and more 83 locations

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Omeprazole
Drug: Midazolam
Drug: Warfarin
Drug: Digoxin
Drug: BI 1181181

First Posted Date: 2015-01-26

Last Posted Date: 2015-03-10

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02345304

Locations: 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: Itraconazole

First Posted Date: 2015-01-21

Last Posted Date: 2015-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02342717

Locations: 🇩🇪
1346.10.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: BI 409306
Drug: Donepezil

First Posted Date: 2015-01-14

Last Posted Date: 2018-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 329

Registration Number: NCT02337907

Locations: 🇫🇷
HOP La Pitié Salpêtrière, Paris, France
🇩🇪
Praxis Dr. med. Volker Schumann, Berlin, Germany
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 57 locations

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: Placebo

First Posted Date: 2015-01-13

Last Posted Date: 2016-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02337283

Locations: 🇩🇪
1346.2.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy